Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (256)	3/23/2005 8:24:12 PM
From: zeta1961	Respond to of 802

I can't for the life of me find that data (presumably from the RPR days), except for a mention of 60% OR in the S-1. Did you mean P1?..sorry, jet lagged and reading papers on cell cycles has me giving different meaning to acronyms.. One of the issues is the whole data set..we investors have T201 and T202 data and then incomplete data on a 3rd P2(100 patients) which they revealed last year(advexin+chemo)which they presented in vague detail at ASGT '04...I've heard(not sure how true but the YMB poster is honest) that Aventis has been muscling INGN around for years since the restructuring of their agreement..a reason the P2's aren't already published because Aventis wouldn't give it to them..In early '03 when I began listening to the CC's Nance mentioned it(politely).. I'll dig up the T201/202 info I do have.. If IMCL cleans INGN's clock at ASCO, perhaps INGN would counterpunch at ASGT (June 1-5), where ImClone can't even get into the ring? Chuckle..hanging 'round Hilary and Clint lately? Comparisons/conclusions with Erbitux and Advexin are difficult.. The P2 Erb from ASCO '04 show similar survival as Advexin(as of last year..there's still an Advexin patient alive 7 years and counting) Erb's was in platinum refractory, unresectable patients..but no CR or PR only Stable or Progressive(I'll dig up the link of my ASCO synopsis)...whereas Advexin P2's have CR/PR's ...the P3 IMCL unveiled last year was in treatment naive using different radiation doses and types of radiation regimens(boost or not and subsequent chemo, surgery) leaving uncertain what influenced the survival..at '04 no subset data available to tease these out..perhaps at '05? I don't believe INGN will publish actionable Advexin abstracts(or on any of their other programs for that matter) ..it's not how Nance does things..But of course that can change.. Yes, ASGT does release abstracts to all at the same time.. Will keep digging! Zeta